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The number of laminopathies is large, and the variability
is equally wide. OMIM mentions 10 different entities,
but there are several additional reports of individuals
with a lamin A/C mutation who have phenotypes that
are still at variance of these.
This variability can be explained in two ways. One is
the widespread dissemination of the lamin A/C protein
within our bodies and indeed within individual cells and
the many functions that is has. The function of provid-
ing firmness to the nuclear envelop is a major function.
A lack of that firmness due to the abnormal protein
causes all structures and proteins in the envelope poten-
tially to be disturbed. These have all kind of functions,
sometimes also completely unrelated, and all can be dis-
turbed by the abnormal lamin A/C only. The other
explanation is the variability between individuals with
changes in the same gene in general. Even brothers and
sisters with exactly the same mutation in exactly the
same gene can still show very different phenotypes. The
background is that it will not be a single gene that
explains the phenotype but also the background of
genetic information of each person, and the exogenous
influences on this, are important. Indeed, “monogenic
disorder do not exist” [1]. So variability should in fact
be expected and also explained to patients.
One can evaluate all laminopathies for their major mani-
festations, which are the heart, muscles, nerves, joints, fat
tissue, skin, bone, morphology of the face, growth and
endocrine functioning. Some laminopathies are explained
by mainly heart and muscle abnormalities, other mainly by
bone, fat, skin, growth and face abnormalities. However, it
may be this distinction is artificial. It may be that in fact
(almost) all laminopathies show signs or symptoms in all
of the above tissues, but we fail to recognize this either
because we haven’t looked carefully enough, or because
patients die for one particularly affected tissue and there-
fore don’t have the time to show the other manifestations
in other tissues. This can be important in evaluating
patients with the various laminopathies, in providing opti-
mal care to them, and in considerations if a management
if applied for one of the consequences of an lamin A/C, as
one cannot exclude others will then arise that have been
unknown until then.
Some may argue that this means in fact all patients
with a laminopathy might be better put under a single
diagnosis. That seems not right. Detailed discussions
about this are available in literature [2]. In addition, the
WHO has decided in the development of the upcoming
new International Classification of Diseases that what
really counts is what a patient experiences from an entity.
And surely it does make a difference if one has an entity
that leads to demise already around birth (restrictive der-
mopathy), leads to significant problems that will be fatal
in puberty (Hutchinson-Gilford progeria), or allow you to
live well into adulthood at least with only limited restric-
tions in well-being (mandibulo-acral dysostosis). So
grouping all disorders under the umbrella laminopathy is
very useful for our insights, but for patients subdivision
into individual entities is still essential.
The grouping into laminopathy has also advantages in
considering various management strategies. In a very
basic way one can divide management into influencing
the abnormal DNA (gene therapy), influencing the
abnormal RNA (mainly through morpholinos and other
small molecules), decreasing the amount of abnormal
protein and/or increasing the amount of normal protein
(by farnesylation inhibition or increasing turnover of pro-
teins), and by influencing the consequences on a cell or
tissue level (for instance by statins). Gradually it becomes
clear that the most effective way must be influencing the
abnormal RNA as the other ways are either undesirable
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(gene therapy) or lack true, curative effectivity (FTIs and
statins). The advantage by working in this way is that stu-
dies for one laminopathy might have benefits for the
other laminopathies as well, and in the end also for all
patients.
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